CN116590376A - Application of eNAMPT on the testis - Google Patents
Application of eNAMPT on the testis Download PDFInfo
- Publication number
- CN116590376A CN116590376A CN202310405812.3A CN202310405812A CN116590376A CN 116590376 A CN116590376 A CN 116590376A CN 202310405812 A CN202310405812 A CN 202310405812A CN 116590376 A CN116590376 A CN 116590376A
- Authority
- CN
- China
- Prior art keywords
- enampt
- testis
- aging
- extracellular vesicles
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001550 testis Anatomy 0.000 title claims abstract description 61
- 230000032683 aging Effects 0.000 claims abstract description 67
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 31
- 210000004027 cell Anatomy 0.000 claims abstract description 21
- 230000014509 gene expression Effects 0.000 claims abstract description 17
- 210000002540 macrophage Anatomy 0.000 claims abstract description 15
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 claims abstract description 12
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 claims abstract description 10
- 230000033228 biological regulation Effects 0.000 claims abstract description 4
- 230000000770 proinflammatory effect Effects 0.000 claims abstract description 4
- 230000003827 upregulation Effects 0.000 claims abstract description 4
- 230000002381 testicular Effects 0.000 claims description 28
- 210000000130 stem cell Anatomy 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 12
- 108010057466 NF-kappa B Proteins 0.000 claims description 10
- 102000003945 NF-kappa B Human genes 0.000 claims description 10
- 238000002474 experimental method Methods 0.000 claims description 8
- 210000003722 extracellular fluid Anatomy 0.000 claims description 8
- 238000005199 ultracentrifugation Methods 0.000 claims description 8
- 238000001262 western blot Methods 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 6
- 238000004458 analytical method Methods 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 239000006143 cell culture medium Substances 0.000 claims description 3
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 claims description 3
- 238000000751 protein extraction Methods 0.000 claims description 3
- 238000001890 transfection Methods 0.000 claims description 3
- 230000001850 reproductive effect Effects 0.000 abstract description 14
- 230000001105 regulatory effect Effects 0.000 abstract description 13
- 230000007246 mechanism Effects 0.000 abstract description 12
- 201000010099 disease Diseases 0.000 abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 238000010171 animal model Methods 0.000 abstract description 4
- 230000009758 senescence Effects 0.000 abstract description 4
- 238000011269 treatment regimen Methods 0.000 abstract description 4
- 230000002028 premature Effects 0.000 abstract description 3
- 230000001276 controlling effect Effects 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 15
- 238000012360 testing method Methods 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 10
- 238000011529 RT qPCR Methods 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 238000004627 transmission electron microscopy Methods 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 description 3
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 3
- 229940124599 anti-inflammatory drug Drugs 0.000 description 3
- 229940109262 curcumin Drugs 0.000 description 3
- 235000012754 curcumin Nutrition 0.000 description 3
- 239000004148 curcumin Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 210000002332 leydig cell Anatomy 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 210000004706 scrotum Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 2
- 108010034143 Inflammasomes Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 206010063493 Premature ageing Diseases 0.000 description 2
- 208000032038 Premature aging Diseases 0.000 description 2
- 229940116193 Protein phosphatase inhibitor Drugs 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004630 mental health Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000003934 phosphoprotein phosphatase inhibitor Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- 102100025222 CD63 antigen Human genes 0.000 description 1
- 102100027221 CD81 antigen Human genes 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 108091054442 EV proteins Proteins 0.000 description 1
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 1
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 101100341513 Mus musculus Itgam gene Proteins 0.000 description 1
- 101001065556 Mus musculus Lymphocyte antigen 6G Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000015532 Nicotinamide phosphoribosyltransferase Human genes 0.000 description 1
- 108010064862 Nicotinamide phosphoribosyltransferase Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010201 enrichment analysis Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000035992 intercellular communication Effects 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004995 male reproductive system Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000037457 pro-inflammatory mechanism Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/5055—Cells of the immune system involving macrophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0683—Cells of the male genital tract, e.g. prostate, epididymis; Non-germinal cells from testis, e.g. Leydig cells, Sertoli cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1077—Pentosyltransferases (2.4.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/02—Pentosyltransferases (2.4.2)
- C12Y204/02012—Nicotinamide phosphoribosyltransferase (2.4.2.12), i.e. visfatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5032—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on intercellular interactions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/04—Immortalised cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/91091—Glycosyltransferases (2.4)
- G01N2333/91142—Pentosyltransferases (2.4.2)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/367—Infertility, e.g. sperm disorder, ovulatory dysfunction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Reproductive Health (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
技术领域technical field
本发明涉及生物医学的技术领域,尤其是指一种eNAMPT在睾丸上的应用。The invention relates to the technical field of biomedicine, in particular to the application of eNAMPT on the testis.
背景技术Background technique
衰老是人体全身以及各个组织器官的病理、生理和心理综合作用的过程,对个体的身心健康造成重大影响,导致个体的身体机能和心理健康下降、增加患病风险和死亡几率。衰老导致各组织器官的衰老,引发相关疾病,常见衰老性疾病包括癌症、高血压、心血管疾病、糖尿病以及各类退行性疾病等。各组织器官并非在人进入老龄时才开始衰老进程,相反,环境和生活方式等因素会导致过早衰老的产生,同样也会使这些组织器官提前进入衰老进程。生殖系统的衰老在人体中是较早开始的,对于男性来说,在整个生命周期中都具有产生配子的能力,因此在更较长的时间中都面临生殖衰老问题。男性生殖系统衰老不仅影响个体自身生殖能力,还直接影响到其它器官的功能,使其它系统机能衰退,导致健康问题;同时还会对个体产生较大的心理问题,影响正常生活;同样重要的是,生产的后代患先天性疾病的风险也将增大。最近的研究发现,在睾丸中,衰老进程与炎症激活有着密切的关系;此外,细胞外囊泡参与细胞间通讯并介导免疫反应并调控免疫微环境。因此,深入研究通过旁分泌途径导致的免疫微环境改变将为睾丸衰老的研究及治疗提供新思路。Aging is a comprehensive process of pathology, physiology and psychology of the whole body and various tissues and organs of the human body, which has a major impact on the physical and mental health of the individual, leading to a decline in the physical function and mental health of the individual, and an increase in the risk of disease and death. Aging leads to the aging of various tissues and organs, leading to related diseases. Common aging diseases include cancer, hypertension, cardiovascular disease, diabetes and various degenerative diseases. Various tissues and organs do not start the aging process when people enter old age. On the contrary, factors such as environment and lifestyle can lead to premature aging, and these tissues and organs will also enter the aging process in advance. The aging of the reproductive system starts earlier in the human body. For males, they have the ability to produce gametes throughout their life cycle, so they face the problem of reproductive aging in a longer period of time. The aging of the male reproductive system not only affects the individual's own reproductive ability, but also directly affects the functions of other organs, causing the function of other systems to decline, leading to health problems; at the same time, it will also cause relatively large psychological problems for the individual, affecting normal life; equally important is , the offspring produced will also have an increased risk of congenital diseases. Recent studies have found that in the testis, the aging process is closely related to the activation of inflammation; moreover, extracellular vesicles participate in intercellular communication and mediate immune responses and regulate the immune microenvironment. Therefore, an in-depth study of the changes in the immune microenvironment caused by the paracrine pathway will provide new ideas for the research and treatment of testicular aging.
细胞外NAMPT(eNAMPT)是一种重要的细胞外介质,eNAMPT水平异常与多种代谢紊乱有关。eNAMPT能够通过影响2型糖尿病反应、细胞凋亡、脂质和葡萄糖代谢、炎症和胰岛素抵抗来调节肥胖和非酒精性脂肪性肝病和氧化应激等相关疾病的发病过程。此外,eNAMPT以功能和结构上不同的单体和二聚体形式循环,二聚体eNAMPT可以促进NAD生物合成,而单体的作用尚不完全清楚,但已有研究证明单体eNAMPT的升高能够通过促炎症机制在饮食诱导糖尿病的发病机制中起重要作用。根据先前的报道,除了酶活性外,eNAMPT在多种信号通路中作为促炎或抗炎细胞因子,如ERK1/2、IL-6-STAT3、PI3K-AKT、p38 MAPK和NF-κB,它们影响多种细胞因子如TNF-α、IL-1β和TGF-β的表达。有研究指出,eNAMPT可以激活独特的toll样受体4(TLR4)诱导NF-κB信号通路,并导致NLRP3的激活,而睾丸巨噬细胞表面同样存在TLR4受体。因此eNAMPT可能在睾丸衰老过程中起到调控作用,随年龄增长大量表达并通过细胞外囊泡途径加速了小鼠睾丸的衰老,但其具体的功能和机制并不清楚。Extracellular NAMPT (eNAMPT) is an important extracellular medium, and the abnormal level of eNAMPT is related to a variety of metabolic disorders. eNAMPT can regulate the pathogenesis of obesity and related diseases such as non-alcoholic fatty liver disease and oxidative stress by affecting type 2 diabetes response, apoptosis, lipid and glucose metabolism, inflammation and insulin resistance. In addition, eNAMPT circulates in functionally and structurally distinct monomers and dimers, and dimerized eNAMPT can promote NAD biosynthesis, while the role of monomers is not fully understood, but studies have demonstrated the elevation of monomeric eNAMPT Can play an important role in the pathogenesis of diet-induced diabetes through pro-inflammatory mechanisms. According to previous reports, in addition to enzymatic activity, eNAMPT acts as pro-inflammatory or anti-inflammatory cytokines in multiple signaling pathways, such as ERK1/2, IL-6-STAT3, PI3K-AKT, p38 MAPK, and NF-κB, which affect Expression of various cytokines such as TNF-α, IL-1β and TGF-β. Studies have pointed out that eNAMPT can activate the unique toll-like receptor 4 (TLR4) to induce NF-κB signaling pathway and lead to the activation of NLRP3, and TLR4 receptors also exist on the surface of testicular macrophages. Therefore, eNAMPT may play a regulatory role in the process of testicular aging. It is expressed in large quantities with age and accelerates the aging of mouse testis through the extracellular vesicle pathway, but its specific function and mechanism are not clear.
目前关于eNAMPT是否可以调节睾丸衰老尚未见报道,本发明发现eNAMPT通过细胞外囊泡途径可以引起睾丸巨噬细胞中NF-κB及NLRP3的差异表达,从而调控睾丸免疫微环境,进而调控衰老相关基因表达,进而影响衰老。本发明为研究男性生殖衰老机制研究打下了坚固的基础,有利于通过细胞模型和动物模型深入研究衰老机制,诊断睾丸相关疾病及开发抗男性生殖衰老或生殖早衰治疗策略。At present, there is no report on whether eNAMPT can regulate testicular aging. The present invention finds that eNAMPT can cause differential expression of NF-κB and NLRP3 in testicular macrophages through the extracellular vesicle pathway, thereby regulating the testicular immune microenvironment, and then regulating aging-related genes expression, thereby affecting aging. The invention lays a solid foundation for the research on the mechanism of male reproductive aging, and is beneficial to in-depth research on aging mechanism through cell models and animal models, diagnosis of testicular related diseases and development of anti-male reproductive aging or premature reproductive aging treatment strategies.
发明内容Contents of the invention
本发明的目的在于克服现有技术的不足,提供一种eNAMPT在睾丸上的应用,通过提取睾丸间质细胞外囊泡并获得了eNAMPT调控睾丸衰老的新作用和新机制,为研究男性生殖衰老机制研究打下了坚固的基础,有利于通过细胞模型和动物模型深入研究衰老机制,诊断睾丸相关疾病及开发抗男性生殖衰老或生殖早衰治疗策略。The purpose of the present invention is to overcome the deficiencies in the prior art, provide a kind of application of eNAMPT on testis, obtain the new effect and new mechanism of eNAMPT regulating testicular aging by extracting interstitial extracellular vesicles of testis, for the research of male reproductive aging Mechanism research has laid a solid foundation, which is conducive to in-depth research on aging mechanisms through cell models and animal models, diagnosis of testicular-related diseases, and development of anti-male reproductive aging or reproductive premature aging treatment strategies.
为实现上述目的,本发明所提供的技术方案如下:eNAMPT在睾丸上的应用,通过过表达的eNAMPT由细胞外囊泡引起睾丸巨噬细胞中NF-κB和NLRP3的上调,使巨噬细胞向促炎表型进行转变,从而调控衰老相关基因的表达,进而影响衰老,实现对睾丸衰老的调控。In order to achieve the above object, the technical scheme provided by the present invention is as follows: the application of eNAMPT on the testis, the up-regulation of NF-κB and NLRP3 in the testicular macrophages caused by the overexpressed eNAMPT from the extracellular vesicles, so that the macrophages can move towards The pro-inflammatory phenotype is transformed, thereby regulating the expression of aging-related genes, thereby affecting aging, and realizing the regulation of testicular aging.
进一步,首先,收集睾丸间质组织液,然后使用差速、超速离心法提取睾丸间质组织液中的细胞外囊泡,随后对睾丸间质细胞外囊泡进行蛋白质提取、液相色谱串联质谱法、蛋白质免疫印迹手段以及蛋白质组学GO或KEGG分析发现eNAMPT在睾丸衰老过程中的差异化表达,进一步通过细胞实验和动物实验的方式实现eNAMPT在睾丸上的应用。Further, firstly, the interstitial tissue fluid of the testis is collected, and then the extracellular vesicles in the interstitial tissue fluid of the testis are extracted using differential speed and ultracentrifugation, and then the extracellular vesicles of the interstitial tissue of the testis are subjected to protein extraction, liquid chromatography tandem mass spectrometry, Western blotting and proteomic GO or KEGG analysis revealed the differential expression of eNAMPT in the testicular aging process, and further realized the application of eNAMPT in testis through cell experiments and animal experiments.
进一步,通过使用慢病毒转染的手段在干细胞中过表达eNAMPT,过表达eNAMPT的干细胞在培养过程中产生过表达eNAMPT的细胞外囊泡,随后通过差速、超速离心法提取干细胞培养液中的过表达eNAMPT细胞外囊泡,进而使用过表达eNAMPT细胞外囊泡通过细胞实验和动物实验的方式实现eNAMPT在睾丸上的应用。Further, eNAMPT was overexpressed in stem cells by means of lentiviral transfection, and eNAMPT-overexpressed stem cells produced extracellular vesicles overexpressing eNAMPT during the culture process, and then the stem cells in the stem cell culture medium were extracted by differential speed and ultracentrifugation. Overexpress eNAMPT extracellular vesicles, and then use the overexpressed eNAMPT extracellular vesicles to realize the application of eNAMPT in testis through cell experiments and animal experiments.
本发明与现有技术相比,具有如下优点与有益效果:Compared with the prior art, the present invention has the following advantages and beneficial effects:
1、本发明通过过表达eNAMPT细胞外囊泡可以引起睾丸巨噬细胞中NF-κB及NLRP3的差异表达,从而调控睾丸免疫微环境,进而调控衰老相关基因表达,进而影响衰老;本发明获得了eNAMPT调控睾丸衰老的新作用和新机制,本发明为研究男性生殖衰老机制研究打下了坚固的基础,有利于通过细胞模型和动物模型深入研究衰老机制,诊断睾丸相关疾病及开发抗男性生殖衰老或生殖早衰治疗策略。1. The present invention can cause the differential expression of NF-κB and NLRP3 in testicular macrophages by overexpressing eNAMPT extracellular vesicles, thereby regulating the immune microenvironment of the testis, and then regulating the expression of aging-related genes, thereby affecting aging; the present invention obtains The new role and new mechanism of eNAMPT regulating testicular aging, the present invention has laid a solid foundation for the study of the mechanism of male reproductive aging, and is conducive to the in-depth study of aging mechanisms through cell models and animal models, the diagnosis of testicular related diseases and the development of anti-male reproductive aging or Treatment strategies for premature reproductive aging.
2、本发明通过差速、超速离心法提取睾丸间质组织液中的细胞外囊泡,进一步发现睾丸间质细胞外囊泡中的蛋白随年龄的差异,从而通过睾丸间质细胞外囊泡开发在睾丸上的应用。2. The present invention extracts the extracellular vesicles in the interstitial tissue fluid of the testis through differential speed and ultracentrifugation, and further discovers the difference of protein in the extracellular vesicles of the interstitium of the testis with age, thereby developing the extracellular vesicles of the interstitial cells of the testis. Application on the testicles.
3、本发明通过在干细胞过表达eNAMPT,随后通过差速、超速离心法提取干细胞培养液中的过表达eNAMPT细胞外囊泡,可以使用个体同源干细胞来源的过表达eNAMPT细胞外囊泡开发在睾丸上的应用。3. In the present invention, by overexpressing eNAMPT in stem cells, and then extracting the overexpressed eNAMPT extracellular vesicles in the stem cell culture medium by differential speed and ultracentrifugation, the overexpressed eNAMPT extracellular vesicles derived from individual homologous stem cells can be used to develop Application on the testicles.
附图说明Description of drawings
图1为实施例1中的年轻与衰老鼠中睾丸间质空间中细胞外囊泡提取及其蛋白组学分析结果图。FIG. 1 is a graph showing the results of extracellular vesicle extraction and proteomic analysis in the interstitial space of the testis in young and aged mice in Example 1.
图2为实施例4中衰老鼠睾丸细胞外囊泡中eNAMPT的过表达调节睾丸巨噬细胞NF-κB及NLRP3基因的表达结果图。Fig. 2 is a graph showing the results of overexpression of eNAMPT in testicular extracellular vesicles of aging mice regulating the expression of NF-κB and NLRP3 genes in testicular macrophages in Example 4.
图3为实施例7中的过表达eNAMPT细胞外囊泡调节睾丸衰老相关基因水平的验证结果图。Fig. 3 is a diagram of verification results of overexpression of eNAMPT extracellular vesicles regulating testicular aging-related gene levels in Example 7.
图4为实施例10在针对干细胞过表达eNAMPT细胞外囊泡调节影响衰老提出抗衰老策略的验证结果图。Fig. 4 is a diagram showing the results of verification of the anti-aging strategy proposed in Example 10 for overexpressing eNAMPT extracellular vesicle regulation in stem cells to affect aging.
图5为实施例13在针对评价年轻与衰老个体睾丸间质细胞外囊泡的验证结果图。Fig. 5 is a diagram of the validation results of Example 13 for evaluating Leydig's extracellular vesicles in young and aging individuals.
具体实施方式Detailed ways
为使本发明的目的、技术方案和优点更清晰明了,下面结合实施例和附图,对本发明作进一步的详细说明,本发明的示意性实施方式仅用于解释本发明,并不作为对发明的限定。In order to make the purpose, technical solutions and advantages of the present invention clearer, the present invention will be further described in detail below in conjunction with the examples and accompanying drawings. limit.
实施例1(一种睾丸间质细胞外囊泡的提取及其表征)Example 1 (extraction and characterization of a Leydig cell extracellular vesicle)
提取年轻小鼠及衰老小鼠睾丸间质细胞外囊泡,利用透射电子显微镜、westernblot、纳米流式细胞仪验证细胞外囊泡的成功提取;随后对提取的衰老小鼠(old)和年轻小鼠(young)睾丸间质细胞外囊泡进行了4DLabel-free非标记蛋白质组学定量分析,主要步骤包括蛋白质提取、蛋白质定量、蛋白质酶解、LC-MS/MS分析、数据库检索和数据分析。分析年轻小鼠组和衰老小鼠组中的蛋白差异,同时通过GO和KEGG分析了衰老小鼠显著上调的蛋白及其所参与的功能。具体步骤如下:Leydig extracellular vesicles were extracted from young mice and aging mice, and the successful extraction of extracellular vesicles was verified by transmission electron microscopy, western blot, and nanometer flow cytometry; Rat (young) Leydig's extracellular vesicles were quantitatively analyzed by 4DLabel-free non-labeled proteomics. The main steps include protein extraction, protein quantification, protein enzymatic hydrolysis, LC-MS/MS analysis, database retrieval and data analysis. The protein differences between the young mouse group and the aging mouse group were analyzed, and the significantly up-regulated proteins and the functions involved in the aging mice were analyzed by GO and KEGG. Specific steps are as follows:
1)断颈处死3月与24月龄的C57BL/6小鼠,用剪刀小心剪开小鼠阴囊,取双侧睾丸同时剔除睾丸上的所有脂肪。1) C57BL/6 mice aged 3 months and 24 months were killed by neck dislocation, the scrotum of the mice was carefully cut open with scissors, and all the fat on the testes was removed from both testes.
2)对每个睾丸进行称重,随后小心在睾丸的白膜上撕开一小口并按每克睾丸加入5mL PBS,在4℃下孵育45min。2) Weigh each testis, then carefully tear a small opening on the albuginea of the testis, add 5 mL of PBS per gram of testis, and incubate at 4° C. for 45 minutes.
3)在4℃下10000g离心15min得到睾丸间质组织液。睾丸间质液进行梯度离心以清除细胞碎片,4℃下2000g离心10min、10000g离心30min、0.22μm过滤除菌后备用。3) Centrifuge at 10,000 g for 15 min at 4°C to obtain the interstitial fluid of the testis. The interstitial fluid of the testis was subjected to gradient centrifugation to remove cell debris, centrifuged at 2000g for 10min at 4°C, 10000g for 30min, and sterilized by 0.22μm filtration before use.
4)转移至超速离心管在200000g下离心2h、用PBS重悬沉淀后在200000g下离心2h,除去上清,得到睾丸间质细胞外囊泡。4) Transfer to an ultracentrifuge tube and centrifuge at 200,000g for 2h, resuspend the pellet with PBS, and centrifuge at 200,000g for 2h, remove the supernatant, and obtain Leydig's extracellular vesicles.
5)吸取样品10μL滴加于铜网上沉淀1min,滤纸吸去浮液。随后吸取钼酸铵溶液10μL滴加于铜网上沉淀1min,滤纸吸去浮液。常温干燥数分钟后在100kV下进行透射电镜成像。5) Take 10 μL of the sample and drop it on the copper grid for precipitation for 1 min, and filter paper to absorb the floating liquid. Then draw 10 μL of ammonium molybdate solution and drop it on the copper grid for precipitation for 1 min, and filter paper absorbs the floating liquid. After several minutes of drying at room temperature, TEM imaging was performed at 100 kV.
6)使用RIPA裂解液(含蛋白磷酸酶抑制剂和PMSF)而不是PBS直接重悬细胞外囊泡沉淀。按前述的方法提取细胞外囊泡中的蛋白,使用BCA蛋白定量试剂盒测定蛋白浓度后,变性、电泳、转膜。随后一抗孵育过夜,次日孵育二抗并曝光显影。6) Use RIPA lysate (containing protein phosphatase inhibitor and PMSF) instead of PBS to directly resuspend the extracellular vesicle pellet. The protein in the extracellular vesicles was extracted according to the aforementioned method, and after the protein concentration was determined using the BCA protein quantification kit, it was denatured, electrophoresed, and transferred to a membrane. Then the primary antibody was incubated overnight, and the secondary antibody was incubated the next day and exposed for imaging.
7)将样品稀释至90μL,各取30μL分别加入20μL荧光标记的抗体(CD63、CD81、IgG),混匀,避光37℃孵育30min。加入1mL预冷的PBS,4℃,110000g,超速离心70min。小心去除上清,加入1mL预冷的PBS,4℃,110000g,再次离心70min。小心去除上清,用50μL预冷的PBS重悬。使用NanoFCM仪器检测蛋白指标结果。7) Dilute the sample to 90 μL, add 20 μL of fluorescently labeled antibodies (CD63, CD81, IgG) to 30 μL each, mix well, and incubate at 37° C. for 30 min in the dark. Add 1mL of pre-cooled PBS, 4°C, 110000g, and ultracentrifuge for 70min. Carefully remove the supernatant, add 1 mL of pre-cooled PBS, centrifuge again at 110,000 g at 4°C for 70 min. Carefully remove the supernatant and resuspend with 50 μL of pre-cooled PBS. Use the NanoFCM instrument to detect protein index results.
8)将每个样品分别加入适量SDT裂解液,转移到EP管中,然后沸水浴3min,超声破碎2min,4℃,16000g离心20min,取上清,使用BCA法进行蛋白定量。每例样品取适量蛋白进行FASP酶解,之后每例样品取适量肽段使用纳升流速Easy nLC 1200色谱系统进行色谱分离。8) Add appropriate amount of SDT lysate to each sample, transfer to EP tube, then boil in water bath for 3 minutes, sonicate for 2 minutes, centrifuge at 16000g for 20 minutes at 4°C, take supernatant, and use BCA method for protein quantification. Take an appropriate amount of protein from each sample for FASP enzymatic hydrolysis, and then take an appropriate amount of peptides from each sample for chromatographic separation using the nanoliter flow rate Easy nLC 1200 chromatographic system.
实施结果见附图1。见附图1中A,本实施案例提取年轻小鼠和衰老小鼠睾丸间质细胞外囊泡。见附图1中B,通过透射电镜、蛋白质印迹western blot和纳米流式细胞仪证实细胞外囊泡的成功提取。见附图1中C,通过年轻小鼠及衰老小鼠睾丸间质细胞外囊泡的聚类分析,提示样本具有一致性,结果稳定。见附图1中D,通过蛋白组学定量分析,确定了衰老小鼠睾丸细胞外囊泡中蛋白组差异。见附图1中E,利用KEGG功能富集分析进一步分析得到烟酸盐和烟酰胺的代谢显示出非常强的富集因子。见附图1中F,进一步分析了细胞外囊泡蛋白中烟酸盐和烟酰胺的代谢及NAD+生物合成中相关蛋白,衰老小鼠睾丸间质细胞外囊泡eNAMPT含量相比年轻小鼠组显著增多了一倍左右,表明eNAMPT与衰老相关。The implementation results are shown in Figure 1. See A in Fig. 1 , this example extracts extracellular vesicles from Leydigm of young mice and aged mice. See B in Figure 1, the successful extraction of extracellular vesicles was confirmed by transmission electron microscopy, western blot and nanometer flow cytometry. See Figure 1, C, clustering analysis of Leydigm extracellular vesicles in young mice and aged mice shows that the samples are consistent and the results are stable. See D in Fig. 1, through proteomics quantitative analysis, the proteome differences in testicular extracellular vesicles of aged mice were determined. See E in Figure 1, the metabolism of nicotinate and nicotinamide showed very strong enrichment factors after further analysis by KEGG functional enrichment analysis. See F in Figure 1. The metabolism of nicotinate and nicotinamide in extracellular vesicle proteins and related proteins in NAD+ biosynthesis were further analyzed. significantly doubled, indicating that eNAMPT is associated with aging.
实施例2Example 2
与实施例1不同的是将超速离心速度由200000g替换成100000g,其它制备条件保持与实施例1一致。提取年轻小鼠及衰老小鼠睾丸间质细胞外囊泡,利用透射电子显微镜、western blot、纳米流式细胞仪验证细胞外囊泡的成功提取。The difference from Example 1 is that the ultracentrifugation speed is replaced by 100,000 g from 200,000 g, and other preparation conditions remain consistent with Example 1. Leydig extracellular vesicles were extracted from young mice and aging mice, and the successful extraction of extracellular vesicles was verified by transmission electron microscopy, western blot, and nanometer flow cytometry.
实施例3Example 3
与实施例1不同的是将超速离心时间由2h替换成1h,其它制备条件保持与实施例1一致。提取年轻小鼠及衰老小鼠睾丸间质细胞外囊泡,利用透射电子显微镜、westernblot、纳米流式细胞仪验证细胞外囊泡的成功提取。The difference from Example 1 is that the ultracentrifugation time is replaced from 2h to 1h, and other preparation conditions remain consistent with Example 1. Leydig extracellular vesicles were extracted from young mice and aging mice, and the successful extraction of extracellular vesicles was verified by transmission electron microscopy, western blot, and nanometer flow cytometry.
实施例4(eNAMPT调控睾丸衰老的作用和机制的研究方法)Embodiment 4 (the research method of the effect and mechanism of eNAMPT regulating testicular aging)
1)断颈处死3月与24月龄的C57BL/6小鼠,用剪刀小心剪开小鼠阴囊,取双侧睾丸同时剔除睾丸上的所有脂肪。1) C57BL/6 mice aged 3 months and 24 months were killed by neck dislocation, the scrotum of the mice was carefully cut open with scissors, and all the fat on the testes was removed from both testes.
2)对每个睾丸进行称重,随后小心在睾丸的白膜上撕开一小口并按每克睾丸加入5mL PBS,在4℃下孵育45min。2) Weigh each testis, then carefully tear a small opening on the albuginea of the testis, add 5 mL of PBS per gram of testis, and incubate at 4° C. for 45 minutes.
3)在4℃下10000g离心15min得到睾丸间质组织液。睾丸间质液进行梯度离心以清除细胞碎片,4℃下2000g离心10min、10000g离心30min、0.22μm过滤除菌后备用。3) Centrifuge at 10,000 g for 15 min at 4°C to obtain the interstitial fluid of the testis. The interstitial fluid of the testis was subjected to gradient centrifugation to remove cell debris, centrifuged at 2000g for 10min at 4°C, 10000g for 30min, and sterilized by 0.22μm filtration before use.
4)转移至超速离心管在200000g下离心2h、用PBS重悬沉淀后在200000g下离心2h,除去上清,得到睾丸间质细胞外囊泡。4) Transfer to an ultracentrifuge tube and centrifuge at 200,000g for 2h, resuspend the pellet with PBS, and centrifuge at 200,000g for 2h, remove the supernatant, and obtain Leydig's extracellular vesicles.
5)将上述样品与生理盐水分别与睾丸巨噬细胞共孵育,24h后取细胞进行qPCR检测。5) The above samples and normal saline were co-incubated with the testicular macrophages respectively, and after 24 hours, the cells were taken for qPCR detection.
6)将上述样品与生理盐水分别注射于年轻小鼠睾丸,三天后处死小鼠并取组织进行qPCR检测。6) The above samples and normal saline were injected into the testes of young mice respectively, and the mice were sacrificed three days later and the tissues were taken for qPCR detection.
7)将上述样品与生理盐水分别注射于年轻小鼠睾丸,三天后处死小鼠取组织后,用IV型胶原酶在37℃下消化15min,并用细胞筛过滤得到睾丸单细胞悬液。用Anti-MouseF4/80FITC抗体和PE-Cyanine7 Anti-Mo CD45抗体标记细胞悬液。洗去抗体后置于冰上,随后使用流式细胞仪检测。7) The above samples and normal saline were injected into the testes of young mice respectively. Three days later, the mice were sacrificed to take the tissues, digested with type IV collagenase at 37° C. for 15 minutes, and filtered with a cell sieve to obtain testicular single cell suspension. Cell suspension was labeled with Anti-MouseF4/80 FITC antibody and PE-Cyanine7 Anti-Mo CD45 antibody. After washing away the antibody, put it on ice, and then use flow cytometry to detect.
8)通过眼眶采集小鼠血液,使用红细胞裂解液去除红细胞,离心去除血细胞后用PBS重悬得到单细胞悬液。用Anti-Human/Mouse CD11b APC抗体和Anti-Mouse Ly-6G(Gr-1)Alexa Fluor488抗体标记细胞悬液。洗去抗体后置于冰上,随后使用流式细胞仪检测。8) The blood of the mouse was collected through the orbit, and the red blood cells were removed by using the red blood cell lysate, and the blood cells were removed by centrifugation, and then resuspended with PBS to obtain a single cell suspension. Cell suspension was labeled with Anti-Human/Mouse CD11b APC antibody and Anti-Mouse Ly-6G(Gr-1) Alexa Fluor488 antibody. After washing away the antibody, put it on ice, and then use flow cytometry to detect.
9)使用eNAMPT重组蛋白5ng/ml处理巨噬细胞,24h后取细胞进行qPCR检测。9) The macrophages were treated with eNAMPT recombinant protein 5ng/ml, and the cells were taken 24 hours later for qPCR detection.
实施结果见附图2。见附图2中A,使用过表达eNAMPT的衰老小鼠睾丸间质细胞外囊泡刺激巨噬细胞,可以显著上调NLRP3及炎症小体相关基因的表达。见附图2中B,使用高表eNAMPT的衰老小鼠睾丸间质细胞注射年轻小鼠,可以显著上调睾丸中NLRP3及炎症小体相关基因的表达,同时上调衰老相关基因表达。见附图2中C,为排除细胞外囊泡中其他物质影响,使用eNAMPT重组蛋白对巨噬细胞进行处理,可以显著上调NF-κB、NLRP3及衰老相关基因,与细胞外囊泡的结果一致。见附图2中D,过表达eNAMPT的细胞外囊泡,可以显著上调睾丸和血液中的炎症细胞。The implementation results are shown in Figure 2. As shown in Figure 2, A, the use of eNAMPT-overexpressed Leydig cells to stimulate macrophages can significantly up-regulate the expression of NLRP3 and inflammasome-related genes. See B in Figure 2, injecting young mice with Leydig cells from aging mice with high expression of eNAMPT can significantly up-regulate the expression of NLRP3 and inflammasome-related genes in the testis, and at the same time up-regulate the expression of aging-related genes. See Figure 2, C. In order to exclude the influence of other substances in extracellular vesicles, macrophages were treated with eNAMPT recombinant protein, which can significantly up-regulate NF-κB, NLRP3 and aging-related genes, which is consistent with the results of extracellular vesicles . See D in Figure 2, extracellular vesicles overexpressing eNAMPT can significantly up-regulate inflammatory cells in testis and blood.
实施例5Example 5
与实施例4不同的是将eNAMPT重组蛋白由5ng/ml替换成500ng/ml,其它条件保持与实施例4一致。The difference from Example 4 is that the eNAMPT recombinant protein was replaced from 5 ng/ml to 500 ng/ml, and other conditions remained consistent with Example 4.
实施例6Example 6
与实施例4不同的是将eNAMPT重组蛋白由5ng/ml替换成250ng/ml,其它条件保持与实施例4一致。The difference from Example 4 is that the eNAMPT recombinant protein was replaced from 5 ng/ml to 250 ng/ml, and other conditions remained consistent with Example 4.
实施例7(构建干细胞过表达eNAMPT细胞外囊泡的方法)Example 7 (Method for constructing stem cells overexpressing eNAMPT extracellular vesicles)
1)提取睾丸来源的干细胞,并在37℃细胞培养箱培养直至稳定。1) Extract testis-derived stem cells and culture them in a 37°C cell incubator until they are stable.
2)使用SV40T对干细胞进行转染做永生化处理,转染后24-72h更换新鲜培养基。2) Stem cells were transfected with SV40T for immortalization, and fresh medium was replaced 24-72 hours after transfection.
3)使用嘌呤霉素对永生化干细胞进行筛选,并通过流式细胞仪检测荧光。3) Puromycin was used to screen the immortalized stem cells, and the fluorescence was detected by flow cytometry.
4)使用eNAMPT慢病毒对干细胞进行转染,待细胞稳定后使用普通培养基继续培养细胞。4) Transfect the stem cells with eNAMPT lentivirus, and continue culturing the cells with ordinary medium after the cells are stabilized.
5)收集细胞上清培养基。4℃下2000g离心10min、10000g离心30min、过滤除菌后转移至超速离心管在200000g下离心2h、用PBS重悬沉淀后在200000g下离心2h,除去上清,提取过表达eNAMPT的细胞外囊泡。5) Collect the cell supernatant medium. Centrifuge at 2000g for 10min at 4°C, centrifuge at 10000g for 30min, filter and sterilize, transfer to an ultracentrifuge tube and centrifuge at 200000g for 2h, resuspend the pellet in PBS and centrifuge at 200000g for 2h, remove the supernatant, and extract the extracellular vesicles overexpressing eNAMPT Bubble.
6)并使用western blot进行检验。6) and use western blot to test.
7)使用上述细胞外囊泡1μg/ml与睾丸巨噬细胞进行共培养,24h后使用细胞进行qPCR检测。7) The extracellular vesicles above 1 μg/ml were used for co-culture with testicular macrophages, and the cells were used for qPCR detection after 24 hours.
实施结果见附图3中A,提取了睾丸来源的干细胞;见附图3中B,对干细胞进行永生化使其易用于培养生产细胞外囊泡;见附图3中C,筛选出永生化的干细胞,表明用于细胞外囊泡生产的永生化干细胞成功构建;见附图3中D,通过western blot表明成功构建了过表达eNAMPT的细胞外囊泡;见附图3中E,通过qPCR证明过表达eNAMPT细胞外囊泡可以上调NF-κB和NLRP3基因,从而上调衰老相关基因,进而影响衰老。表明过表达eNAMPT细胞外囊泡可以诱导睾丸衰老。The results of the implementation are shown in A in Figure 3, where testis-derived stem cells are extracted; in B in Figure 3, stem cells are immortalized to make them easy to be used for culturing and producing extracellular vesicles; in C in Figure 3, immortalized cells are screened out The transformed stem cells indicate that the immortalized stem cells used for the production of extracellular vesicles were successfully constructed; see D in the accompanying drawing 3, and the extracellular vesicles overexpressing eNAMPT were successfully constructed by western blot; see E in the accompanying drawing 3, through qPCR proved that overexpression of eNAMPT extracellular vesicles can up-regulate NF-κB and NLRP3 genes, thereby up-regulating aging-related genes, and then affecting aging. It was shown that overexpression of eNAMPT extracellular vesicles could induce testicular senescence.
实施例8Example 8
与实施例7不同的是将过表达eNAMPT的细胞外囊泡由1μg/ml替换成10μg/ml,其它条件保持与实施例7一致。The difference from Example 7 is that the extracellular vesicles overexpressing eNAMPT were replaced from 1 μg/ml to 10 μg/ml, and other conditions remained the same as in Example 7.
实施例9Example 9
与实施例7不同的是将过表达eNAMPT的细胞外囊泡由1μg/ml替换成100μg/ml,其它条件保持与实施例7一致。The difference from Example 7 is that the extracellular vesicles overexpressing eNAMPT were replaced from 1 μg/ml to 100 μg/ml, and other conditions remained the same as in Example 7.
实施例10(通过抗炎药物对诱导衰老后的睾丸进行治疗)Embodiment 10 (Treat the testis after induction of aging by anti-inflammatory drugs)
1)收集细胞上清培养基。4℃下2000g离心10min、10000g离心30min、过滤除菌后转移至超速离心管在200000g下离心2h、用PBS重悬沉淀后在200000g下离心2h,除去上清,提取过表达eNAMPT的细胞外囊泡。1) Collect the cell supernatant medium. Centrifuge at 2000g for 10min at 4°C, centrifuge at 10000g for 30min, filter and sterilize, transfer to an ultracentrifuge tube and centrifuge at 200000g for 2h, resuspend the pellet in PBS and centrifuge at 200000g for 2h, remove the supernatant, and extract the extracellular vesicles overexpressing eNAMPT Bubble.
2)使用eNAMPT重组蛋白注射年轻小鼠睾丸,同时注射抗炎药物姜黄素。2) The eNAMPT recombinant protein was used to inject the testes of young mice, and the anti-inflammatory drug curcumin was injected at the same time.
3)3天后收集组织进行ELISA检测炎症因子水平和qPCR检测衰老相关基因水平。3) After 3 days, the tissues were collected for ELISA to detect the levels of inflammatory factors and qPCR to detect the levels of aging-related genes.
实施结果见附图4,通过ELISA和qPCR证明抗炎治疗可以通过阻断炎症因子的释放,从而改善衰老相关基因上调,具有抗衰老作用。由于eNAMPT通过上调NF-κB进而激活NLRP3,从而释放炎症因子,导致免疫微环境的改变,进而上调衰老相关基因影响衰老。使用抗炎药物可以通过降低炎症基因表达改善衰老相关基因的表达。The results of the implementation are shown in Figure 4. ELISA and qPCR prove that anti-inflammatory treatment can block the release of inflammatory factors, thereby improving the upregulation of aging-related genes and having anti-aging effects. Because eNAMPT activates NLRP3 by up-regulating NF-κB, thereby releasing inflammatory factors, leading to changes in the immune microenvironment, and then up-regulating aging-related genes to affect aging. The use of anti-inflammatory drugs can improve the expression of aging-related genes by reducing the expression of inflammatory genes.
实施例11Example 11
与实施例10不同的是将姜黄素替换成白藜芦醇,其它条件保持与实施例8一致。The difference from Example 10 is that curcumin is replaced by resveratrol, and other conditions remain consistent with Example 8.
实施例12Example 12
与实施例11不同的是将姜黄素替换成雷帕霉素,其它条件保持与实施例8一致。The difference from Example 11 is that curcumin is replaced by rapamycin, and other conditions remain consistent with Example 8.
实施例13(使用睾丸间质细胞外囊泡进行诊断)Example 13 (diagnosis using Leydig's extracellular vesicles)
1)断颈处死3月与24月龄的C57BL/6小鼠,用剪刀小心剪开小鼠阴囊,取双侧睾丸同时剔除睾丸上的所有脂肪。1) C57BL/6 mice aged 3 months and 24 months were killed by neck dislocation, the scrotum of the mice was carefully cut open with scissors, and all the fat on the testes was removed from both testes.
2)对每个睾丸进行称重,随后小心在睾丸的白膜上撕开一小口并按每克睾丸加入5mL PBS,在4℃下孵育45min。2) Weigh each testis, then carefully tear a small opening on the albuginea of the testis, add 5 mL of PBS per gram of testis, and incubate at 4° C. for 45 minutes.
3)在4℃下10000g离心15min得到睾丸间质组织液。睾丸间质液进行梯度离心以清除细胞碎片,4℃下2000g离心10min、10000g离心30min、0.22μm过滤除菌后备用。3) Centrifuge at 10,000 g for 15 min at 4°C to obtain the interstitial fluid of the testis. The interstitial fluid of the testis was subjected to gradient centrifugation to remove cell debris, centrifuged at 2000g for 10min at 4°C, 10000g for 30min, and sterilized by 0.22μm filtration before use.
4)转移至超速离心管在200000g下离心2h、用PBS重悬沉淀后在200000g下离心2h,除去上清,得到睾丸间质细胞外囊泡。4) Transfer to an ultracentrifuge tube and centrifuge at 200,000g for 2h, resuspend the pellet with PBS, and centrifuge at 200,000g for 2h, remove the supernatant, and obtain Leydig's extracellular vesicles.
5)使用RIPA裂解液(含蛋白磷酸酶抑制剂和PMSF)而不是PBS直接重悬细胞外囊泡沉淀。按前述的方法提取细胞外囊泡中的蛋白,使用BCA蛋白定量试剂盒测定蛋白浓度后,变性、电泳、转膜。随后一抗孵育过夜,次日孵育二抗并曝光显影。5) Use RIPA lysate (containing protein phosphatase inhibitor and PMSF) instead of PBS to directly resuspend the extracellular vesicle pellet. The protein in the extracellular vesicles was extracted according to the aforementioned method, and after the protein concentration was determined using the BCA protein quantification kit, it was denatured, electrophoresed, and transferred to a membrane. Then the primary antibody was incubated overnight, and the secondary antibody was incubated the next day and exposed for imaging.
实施结果见附图5,衰老鼠中睾丸间质细胞外囊泡表达eNAMPT单体含量显著提高,可作为睾丸衰老判断标准。按照此方法可以根据特定指标判断睾丸其它相关疾病。The results of the implementation are shown in Figure 5. The eNAMPT monomer content expressed in the extracellular vesicles of the Leydigm of the testes in aging mice was significantly increased, which can be used as a criterion for judging testicular aging. According to this method, other related diseases of the testis can be judged according to specific indicators.
以上所述之实施例子只为本发明之较佳实施例,并非以此限制本发明的实施范围,故凡依本发明之形状、原理所作的变化,均应涵盖在本发明的保护范围内。The implementation examples described above are only preferred embodiments of the present invention, and are not intended to limit the scope of the present invention. Therefore, all changes made according to the shape and principle of the present invention should be covered within the scope of protection of the present invention.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310405812.3A CN116590376A (en) | 2023-04-17 | 2023-04-17 | Application of eNAMPT on the testis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310405812.3A CN116590376A (en) | 2023-04-17 | 2023-04-17 | Application of eNAMPT on the testis |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116590376A true CN116590376A (en) | 2023-08-15 |
Family
ID=87610637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310405812.3A Pending CN116590376A (en) | 2023-04-17 | 2023-04-17 | Application of eNAMPT on the testis |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116590376A (en) |
-
2023
- 2023-04-17 CN CN202310405812.3A patent/CN116590376A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cai et al. | hucMSC-derived exosomes attenuate colitis by regulating macrophage pyroptosis via the miR-378a-5p/NLRP3 axis | |
Zhang et al. | Aquaporin-4 independent Kir4. 1 K+ channel function in brain glial cells | |
Ishimoto et al. | Serum from minimal change patients in relapse increases CD80 expression in cultured podocytes | |
Lee et al. | Elevated peripheral myelin protein 22, reduced mitotic potential, and proteasome impairment in dermal fibroblasts from Charcot-Marie-Tooth disease type 1A patients | |
Tien et al. | Association of reduced Connexin 43 expression with retinal vascular lesions in human diabetic retinopathy | |
Lau et al. | Blood–brain barrier alterations and their impact on Parkinson’s disease pathogenesis and therapy | |
Wu et al. | Metabolic reprogramming orchestrates CD4+ T-cell immunological status and restores cardiac dysfunction in autoimmune induced-dilated cardiomyopathy mice | |
Gorman | The adrenal gland: common disease states and suspected new applications | |
CN111304171B (en) | Nicotinic acetylcholine receptor targeted overexpressed circDYM exosomes and preparation method and application thereof | |
US10093898B2 (en) | Purification of functional human astrocytes | |
Sundaram et al. | Differential expression patterns of sodium potassium ATPase alpha and beta subunit isoforms in mouse brain during postnatal development | |
Zhao et al. | The changes of potassium currents in RCS rat Müller cell during retinal degeneration | |
Kirian et al. | Extracellular vesicles as carriers of mRNA: Opportunities and challenges in diagnosis and treatment | |
Brunet et al. | Validating fluorescent Chrnb4. EGFP mouse models for the study of cone photoreceptor degeneration | |
Thierry et al. | Early adaptive response of the retina to a pro-diabetogenic diet: Impairment of cone response and gene expression changes in high-fructose fed rats | |
Venugopal et al. | Ouabain promotes partial epithelial to mesenchymal transition (EMT) changes in human autosomal dominant polycystic kidney disease (ADPKD) cells | |
King et al. | Vitreous IGFBP-3 effects on Müller cell proliferation and tractional force generation | |
Xu et al. | Interaction of Wip1 and NF-κB regulates neuroinflammatory response in astrocytes | |
CN116590376A (en) | Application of eNAMPT on the testis | |
Li et al. | Neu-P11—a novel melatonin receptor agonist, could improve the features of type-2 diabetes mellitus in rats | |
CN109868313A (en) | Application of the HMGA2 gene in Stein-Leventhal syndrome disease | |
Ko et al. | Signal transducer and activator of transcription 3 as a potential therapeutic target for Graves’ orbitopathy | |
Wang et al. | Proteomic evidence that ABCA4 is vital for traumatic proliferative vitreoretinopathy formation and development | |
Bandyopadhyay et al. | Photoreceptor structure and function is maintained in organotypic cultures of mouse retinas | |
Fenster et al. | Modulation of Kv4. 2 K+ currents by neuronal interleukin-16, a PDZ domain-containing protein expressed in the hippocampus and cerebellum |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |